Dr. Reddy’s Laboratories has launched Dimethyl Fumarate Delayed-Release Capsules, a therapeutic equivalent generic version of Tecfidera (dimethyl fumarate) Delayed-Release Capsules, approved by the U.S. Food and Drug Administration (USFDA).
The Tecfidera brand and generic market had U.S. sales of approximately $3.8 billion MAT for the most recent twelve months ending in June 2020, according to IQVIA Health. The company’s Dimethyl Fumarate Delayed-Release Capsules are available in 120 mg and 240 mg capsules in bottle count sizes of 14 and 60 capsules, respectively.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1865.95 |
| Dr. Reddys Labs. | 1339.35 |
| Cipla | 1456.95 |
| Zydus Lifesciences | 1108.85 |
| Lupin | 2396.50 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: